AAX Biotech announces collaboration for cardiovascular antibody therapy
Ella Day | May 8, 2025 | News story | Research and Development |Â Â AAX Biotech, Cardiology, antibody therapies, collaboration, research and developmentÂ
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of antibody-based therapies targeting cardiovascular disease.
As part of the agreement, AAX Biotech will apply its proprietary Seqitope technology to support the clinical development of an antibody currently undergoing trials. The technology offers high-resolution epitope mapping, which provides detailed insight into antibody-antigen interactions. This data is used to refine antibody specificity, reduce off-target effects and assist with regulatory submissions.
Epitope mapping is considered an essential step in antibody development, particularly at clinical stages, where precision and consistency are critical for evaluation and approval of the therapy.
The collaboration reflects AAX Biotech’s broader mission to advance the design and development of antibody-based medicines. Alongside Seqitope, the company’s other leading asset is Opti-mAb, a technology designed to stabilise antibody formats such as bispecific antibodies and CAR T-cells.
“We are pleased to support our partner in this important phase of their drug candidate’s clinical development,” says Maria Lisa Knudsen, CEO of AAX Biotech. She added: “With Seqitope, we provide the precision needed to optimise antibody characterisation and we look forward to supporting their continued progress.”
Ella Day
8/5/25
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
AAX Biotech and ToxoTech partner to develop next-gen biotherapeutics for neurological disorders
AAX Biotech, a biotech company specialising in next-generation antibody therapeutics, has entered a strategic partnership …
